Cargando…

Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer

PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose...

Descripción completa

Detalles Bibliográficos
Autores principales: Dent, Susan F., Morse, Amber, Burnette, Sarah, Guha, Avirup, Moore, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395382/
https://www.ncbi.nlm.nih.gov/pubmed/34453232
http://dx.doi.org/10.1007/s11912-021-01114-x
_version_ 1783744158820728832
author Dent, Susan F.
Morse, Amber
Burnette, Sarah
Guha, Avirup
Moore, Heather
author_facet Dent, Susan F.
Morse, Amber
Burnette, Sarah
Guha, Avirup
Moore, Heather
author_sort Dent, Susan F.
collection PubMed
description PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose a cardiac monitoring (CM) strategy for this population. RECENT FINDINGS: Long-term data from studies with HER2-targeted therapy in the adjuvant setting have failed to demonstrate an increase in cardiotoxicity over time, and rates of cardiotoxicity seen with novel HER2 agents remain low. Despite over a decade of experience with HER2-targeted therapy, CM in clinical practice is inconsistent in patients with early BC and almost non-existent in advanced BC. SUMMARY: Long-term follow-up of clinical trials with HER2-targeted agents in early and advanced BC has failed to demonstrate increased rates of cardiotoxicity over time, attesting to the long-term safety of this class of drugs for the majority of patients, although the long-term cardiac safety of newer HER2 agents in the non-clinical trial setting is largely unknown. We propose CM incorporating clinical history, cardiac imaging, and biomarkers.
format Online
Article
Text
id pubmed-8395382
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-83953822021-08-27 Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer Dent, Susan F. Morse, Amber Burnette, Sarah Guha, Avirup Moore, Heather Curr Oncol Rep Cardio-oncology (EH Yang, Section Editor) PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose a cardiac monitoring (CM) strategy for this population. RECENT FINDINGS: Long-term data from studies with HER2-targeted therapy in the adjuvant setting have failed to demonstrate an increase in cardiotoxicity over time, and rates of cardiotoxicity seen with novel HER2 agents remain low. Despite over a decade of experience with HER2-targeted therapy, CM in clinical practice is inconsistent in patients with early BC and almost non-existent in advanced BC. SUMMARY: Long-term follow-up of clinical trials with HER2-targeted agents in early and advanced BC has failed to demonstrate increased rates of cardiotoxicity over time, attesting to the long-term safety of this class of drugs for the majority of patients, although the long-term cardiac safety of newer HER2 agents in the non-clinical trial setting is largely unknown. We propose CM incorporating clinical history, cardiac imaging, and biomarkers. Springer US 2021-08-27 2021 /pmc/articles/PMC8395382/ /pubmed/34453232 http://dx.doi.org/10.1007/s11912-021-01114-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Cardio-oncology (EH Yang, Section Editor)
Dent, Susan F.
Morse, Amber
Burnette, Sarah
Guha, Avirup
Moore, Heather
Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
title Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
title_full Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
title_fullStr Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
title_full_unstemmed Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
title_short Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
title_sort cardiovascular toxicity of novel her2-targeted therapies in the treatment of breast cancer
topic Cardio-oncology (EH Yang, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395382/
https://www.ncbi.nlm.nih.gov/pubmed/34453232
http://dx.doi.org/10.1007/s11912-021-01114-x
work_keys_str_mv AT dentsusanf cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer
AT morseamber cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer
AT burnettesarah cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer
AT guhaavirup cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer
AT mooreheather cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer